A previously underappreciated population of immature T cells may help explain why type 2 inflammation in the lungs can persist long after its initiating trigger has disappeared. In a study published in Nature Immunology, researchers report that progenitor T cells are not merely passive intermediates waiting to mature. Instead, these cells can actively contribute to chronic pulmonary inflammation, sustaining immune programs associated with asthma, allergic disease and other type 2 inflammatory disorders. The findings broaden the conventional view of T-cell biology by suggesting that cells positioned early in the T-cell developmental pathway can influence long-term immune activity in tissues. Rather than treating inflammation as the work of fully differentiated effector cells alone, the study places progenitor populations at the center of a process that may determine how the lung responds repeatedly to environmental challenges.
Type 2 inflammation is characterized by the coordinated activity of immune cells and signaling molecules that protect against large extracellular parasites but can become harmful when activated inappropriately. In the lungs, this response commonly involves type 2 helper T cells, eosinophils, innate lymphoid cells and epithelial cells that release alarm signals after detecting damage or allergens. Cytokines such as interleukin-4, interleukin-5 and interleukin-13 then amplify the response. Interleukin-5 promotes the production, recruitment and survival of eosinophils, while interleukin-13 can increase mucus production, alter airway smooth-muscle behavior and drive structural remodeling. These changes may help expel pathogens under acute conditions, but persistent signaling can narrow the airways and make the respiratory system hypersensitive. The new work indicates that progenitor T cells can participate in this inflammatory circuitry, potentially creating a cellular reservoir capable of renewing or reinforcing type 2 responses over time.
T-cell progenitors are developmentally flexible cells that have not yet acquired the full characteristics of mature T-cell subsets. In the thymus, immature precursors undergo a series of selection and differentiation steps, ultimately producing populations with specialized functions. Some descendants become conventional CD4 or CD8 T cells, while others acquire regulatory, innate-like or tissue-adapted properties. The researchers’ observations suggest that this developmental flexibility may remain relevant after T-cell progenitors enter or influence peripheral tissues. Under inflammatory conditions, progenitor cells may receive signals from lung epithelial cells, antigen-presenting cells and cytokine networks that guide their behavior. Instead of immediately differentiating into a single terminal state, they may retain the ability to generate cells with type 2 inflammatory activity, allowing the response to be renewed when mature effector cells decline.
The biological importance of this mechanism lies in the difference between maintaining inflammation and initiating it. A first exposure to an allergen, irritant or infectious insult can activate epithelial alarm pathways and recruit immune cells. However, chronic disease requires additional processes that preserve immune memory, maintain cytokine production and repeatedly restore effector populations. Progenitor T cells could help fill this role by functioning as a source of replacement cells or by directly producing inflammatory mediators while retaining developmental potential. Such cells may be particularly valuable in tissues where immune conditions change rapidly. The lung is continuously exposed to inhaled particles, microbes and pollutants, so it must balance rapid defense with mechanisms that prevent excessive injury. The study suggests that progenitor populations can become embedded in this balance and, under persistent stimulation, may support inflammation instead of resolution.
The researchers used experimental approaches designed to identify the contribution of progenitor T cells to pulmonary type 2 inflammation and distinguish it from the activity of mature lymphocytes. These approaches included cellular profiling and functional analyses that track immune populations in the lung during inflammatory responses. By examining the molecular features of T cells at different developmental stages, the study could assess which cells expressed type 2-associated programs and whether progenitor populations changed in abundance or behavior during chronic inflammation. Such analyses are important because conventional immune markers can make immature and mature cells appear similar, particularly when progenitors acquire activation-associated proteins. Functional experiments provided an additional layer of evidence by testing whether these cells were necessary for sustaining inflammatory responses rather than simply appearing as a consequence of tissue damage.
At the molecular level, the findings are consistent with a model in which progenitor T cells respond to local signals and contribute to the production or maintenance of type 2 cytokine networks. Lung inflammation is not controlled by a single pathway. It arises from interactions among antigen receptors, cytokine receptors, transcription factors and metabolic programs that determine how a T cell survives and functions. Signals transmitted through receptors for interleukins and other inflammatory mediators can activate transcriptional regulators that promote cytokine expression and cellular proliferation. At the same time, tissue-derived factors may preserve a less differentiated state, allowing a cell to continue generating descendants with different functional properties. This combination of inflammatory activity and developmental flexibility could make progenitor T cells especially effective at maintaining long-lasting responses. It may also explain why inflammation can recur even after conventional effector cells have been reduced.
The study has potential implications for diseases in which type 2 inflammation becomes chronic or relapsing. Asthma is the most immediate example, but similar immune programs occur in allergic airway disease, chronic rhinosinusitis and certain forms of pulmonary inflammation associated with environmental exposure. Current treatments often target downstream cytokines or broadly suppress immune activity. Biologic drugs that neutralize interleukin-5, interleukin-4 receptor signaling or related pathways can reduce disease activity in selected patients, yet responses vary and inflammation may return when treatment stops. If progenitor T cells act as a durable source of type 2 immunity, then blocking cytokines after they are produced may not be sufficient for every patient. Therapies that alter progenitor-cell survival, localization, differentiation or responsiveness to lung-derived signals could provide a complementary strategy. Such interventions would need to be carefully designed, because progenitor populations may also contribute to protective immunity and tissue repair.
The findings also raise questions about how immune memory should be defined. Traditional models emphasize long-lived memory T cells that are generated after an immune response and rapidly reactivate when the same antigen is encountered. Progenitor T cells suggest a more flexible form of immune persistence, in which a population retains the capacity to produce different types of descendants while remaining responsive to the tissue environment. This flexibility could be beneficial during repeated exposure to changing threats, because it allows the immune system to adapt without rebuilding its response from the beginning. In chronic disease, however, the same property could become maladaptive. A progenitor pool might preserve inflammatory potential even when the original antigen is no longer prominent, especially if epithelial damage and cytokine production continue to provide activating signals.
Further research will be needed to determine whether the mechanism described in the study operates in human lungs and whether it differs among patients with distinct forms of respiratory disease. Human tissues contain a wider range of exposures, genetic backgrounds and treatment histories than experimental models, all of which can influence T-cell development and behavior. Researchers will also need to establish whether progenitor T cells can be identified reliably using markers that distinguish them from activated effector and memory cells. Mapping their location within lung tissue may reveal whether they concentrate near airways, blood vessels, epithelial lesions or lymphoid structures. Longitudinal studies could determine whether their abundance predicts future exacerbations or treatment resistance. By identifying progenitor T cells as potential drivers of sustained type 2 inflammation, the work offers a new framework for understanding why pulmonary immune responses sometimes fail to switch off—and points toward therapies aimed not only at inflammatory signals, but also at the cellular sources that keep those signals alive.
Subject of Research: Progenitor T cells and chronic pulmonary type 2 inflammation
Article Title: Progenitor T cells drive chronic pulmonary type 2 inflammation
Article References: Kratchmarov, R., Jia, X., Nagai, J. et al. Progenitor T cells drive chronic pulmonary type 2 inflammation. Nature Immunology 27, 1913–1929 (2026). https://doi.org/10.1038/s41590-026-02619-y
Image Credits: AI Generated
DOI: 10.1038/s41590-026-02619-y
Keywords: progenitor T cells, pulmonary inflammation, type 2 immunity, asthma, cytokines, eosinophils, lung immunology, allergic disease, T-cell differentiation, immune memory
Tags: chronic lung inflammationcytokine signaling in type 2 inflammatory disordersenvironmental challenges and lung immune responseeosinophils and epithelial cells in allergic reactionsimmune cell contribution to asthma persistenceimmune programs in allergic lung diseaseinnate lymphoid cells in lung inflammationlong-term immune activity in lungsprogenitor T cells in immune responserole of immature T cells in asthmaT-cell development in pulmonary inflammationtype 2 inflammation mechanisms
